Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen has delivered a 647% total return since 2011 and maintained a solid 10.04% 5-Year Dividend Growth Rate. Amid short-term product decisions and sales variations driving down operational efficie...

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp. N...

Amgen's stock price has surged, driven by strategic acquisitions, a diverse medical portfolio, and a focus on AI innovation, positioning it for substantial long-term growth. Amgen's strong performa...

Amgen (AMGN) reachead $307.81 at the closing of the latest trading day, reflecting a +1.09% change compared to its last close.

The U.S. health regulator said on Friday it has revised the prescribing information on Amgen's drug to treat bone loss to include a boxed warning related to risk of severely low calcium level in ce...

Amgen (AMGN) closed the most recent trading day at $304.08, moving +0.2% from the previous trading session.

The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.

Amgen (AMGN) reachead $303.10 at the closing of the latest trading day, reflecting a -0.48% change compared to its last close.

Here are three stocks in the health care sector that could provide further upside potential based on their improving technical characteristics.

“The Dogs of the Dow” system involves purchasing the index's 10 stocks with the highest dividend yields at the end of each year. Using the technique has a few major advantages.

Xeris Biopharma Holdings (NASDAQ:XERS) announced an exclusive worldwide license agreement with Amgen for the development, manufacturing, and commercialization of a subcutaneous formulation of tepro...

Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups sin...